

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Zhaoke Ophthalmology Limited
兆科眼科有限公司

(Incorporated in the British Virgin Islands with limited liability and continued in the Cayman Islands)
(Stock Code: 6622)

VOLUNTARY ANNOUNCEMENT –
ADVANCING COMMERCIALIZATION OF BRIMOCHOL™ PF
FOR PRESBYOPIA IN SINGAPORE AND VIETNAM
THROUGH PARTNERSHIPS WITH AFT AND SENJU

This announcement is made by the board of directors (the “**Board**”) of Zhaoke Ophthalmology Limited (the “**Company**”) on a voluntary basis.

The Board of the Company is pleased to announce that the Company has expanded its partnership agreement with the leading manufacturer and distributor of healthcare products, AFT Pharmaceuticals Limited (“**AFT**”), for commercializing BRIMOCHOL™ PF (the “**Product**”) in Singapore. The Company has also established a strategic partnership with leading Asian ophthalmology company Senju Pharmaceutical Co., Ltd. (“**Senju**”) for the commercialization of the Product in Vietnam.

Zhaoke is granting AFT and Senju, exclusive distribution rights in Singapore and Vietnam respectively, which include the right to register, import, promote, distribute, market, and sell BRIMOCHOL™ PF in their corresponding markets. With these agreements, AFT and Senju become the 7th and 8th commercialization partners for BRIMOCHOL™ PF, underscoring our extensive commitment to global expansion.

BRIMOCHOL™ PF is a potential treatment to correct the loss of near vision associated with presbyopia, which is the Company’s core asset licensed from its partner Tenpoint Therapeutics, Ltd. (“**Tenpoint**”), a global, commercial-ready biotechnology company developing groundbreaking treatments to rejuvenate vision in the aging eye. In June 2025, Tenpoint announced that the U.S. FDA accepted its New Drug Application (“**NDA**”). The FDA has set a Prescription Drug User Fee Act (“**PDUFA**”) date of January 28, 2026 for BRIMOCHOL™ PF.

ABOUT BRIMOCHOL™ PF AND BRIO-II PHASE 3 STUDY

BRIMOCHOL™ PF is an investigational, preservative-free, once daily eyedrop to correct for the loss of near vision associated with aging. BRIO-II is a 3-arm, multicenter, randomized, double-masked, safety and efficacy study of BRIMOCHOL™ PF (carbachol/brimonidine tartrate fixed-dose combination) topical ophthalmic solution vs. carbachol monotherapy topical ophthalmic solution vs. a vehicle topical ophthalmic solution in subjects with emmetropic phakic or pseudophakic presbyopia (NCT05135286). The study enrolled 629 subjects across forty-seven sites in the United States.

ABOUT PRESBYOPIA

Presbyopia is the gradual loss of near vision associated with aging, making it difficult to perform tasks like reading fine print. It typically begins in adults in their 40s¹ and becomes almost universal by age 50². Presbyopia impacts billions of people globally³ with approximately 600 million adults affected in China, South Korea and Southeast Asia⁴. In Australia, the total number of prevalence cases reached over 13.5 million in 2023, according to GlobalData⁵. Reading glasses are the most common solution for near-vision correction; however, many people find glasses inconvenient or prefer not to wear them for aesthetic reasons. There are currently no approved presbyopia-correcting therapeutics in many countries across the Asia-Pacific region.

ABOUT AFT PHARMACEUTICALS LIMITED

AFT is a growing New Zealand based multinational pharmaceutical company that develops, markets, and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over the counter (OTC), prescription and hospital. Its product portfolio comprises both proprietary and in-licensed products, and includes patented, branded, and generic drugs. Its business model is to develop and in-license products for the markets of Australia, New Zealand, Singapore, Malaysia, Hong Kong, USA, Canada, EU ex Ireland and UK, and to out-license its products to local licensees and distributors to over 125 countries around the world. For more information about the company, please visit www.aftpharm.com.

¹ World report on vision. (2019). Retrieved April 29, 2022, from https://www.who.int/docs/default-source/documents/world-vision-report-post-launch-accessible.pdf?sfvrsn=1b29f0e7_2

² Polat, U., Schor, C., Tong, J.L. et al. Training the brain to overcome the effect of aging on the human eye. *Sci Rep* 2, 278 (2012). <https://doi.org/10.1038/srep00278>

³ Market Scope, Global Presbyopia-Correcting Surgery Market Report. April 2012

⁴ Tenpoint Therapeutics data on file

⁵ GlobalData's Epidemiology Market Size Search extracted on December 18, 2024

ABOUT SENJU PHARMACEUTICAL CO., LTD.

Senju is a privately held, research-based Japanese pharmaceutical company that develops, manufactures, and commercializes a variety of innovative products, focusing on the field of ophthalmology to improve the health and quality of vision for people worldwide. The characters that comprise Senju's company name in the Japanese language are "Sen" and "Ju", or "thousand" and "bringing happiness". Senju's mission is to improve the joy of living of people associated with the company through the development of original pharmaceutical products. Senju is headquartered in Osaka, Japan, and has its subsidiaries and representative offices around the world. More on www.senju.co.jp/english/.

Cautionary statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will ultimately develop, or commercialize BRIMOCHOL™ PF successfully. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Zhaoke Ophthalmology Limited
Dr. Li Xiaoyi
Chairman

Hong Kong, January 26, 2026

As at the date of this announcement, the Board of the Company comprises Dr. Li Xiaoyi and Mr. Dai Xiangrong as executive Directors; Ms. Leelalertsuphakun Wanee and Ms. Tiantian Zhang as non-executive Directors; and Mr. Wong Hin Wing, Prof. Lo Yuk Lam and Mr. Liew Fui Kiang as independent non-executive Directors.